Bank of America’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-111
| Closed | -$2K | – | 7476 |
|
|
2018
Q4 | $2K | Hold |
111
| – | – | ﹤0.01% | 6913 |
|
|
2018
Q3 | $2K | Buy |
+111
| New | +$3.38K | ﹤0.01% | 7049 |
|
|
2018
Q2 | – | Sell |
-5,844
| Closed | -$381K | – | 7379 |
|
|
2018
Q1 | $381K | Sell |
5,844
-5,278
| -47% | -$374K | ﹤0.01% | 5004 |
|
|
2017
Q4 | $812K | Buy |
11,122
+266
| +2% | +$22K | ﹤0.01% | 4617 |
|
|
2017
Q3 | $995K | Buy |
+10,856
| New | +$833K | ﹤0.01% | 4511 |
|
|
2015
Q1 | – | Sell |
-311
| Closed | -$111K | – | 7659 |
|
|
2014
Q4 | $111K | Buy |
311
+22
| +8% | +$6.55K | ﹤0.01% | 5800 |
|
|
2014
Q3 | $56K | Sell |
289
-133
| -32% | -$29.2K | ﹤0.01% | 6429 |
|
|
2014
Q2 | $101K | Sell |
422
-122
| -22% | -$24.8K | ﹤0.01% | 6139 |
|
|
2014
Q1 | $139K | Buy |
544
+400
| +278% | +$122K | ﹤0.01% | 5716 |
|
|
2013
Q4 | $29K | Buy |
+144
| New | +$25.6K | ﹤0.01% | 6862 |
|
|
2013
Q3 | – | Sell |
-2,222
| Closed | -$394K | – | 8064 |
|
|
2013
Q2 | $394K | Buy |
+2,222
| New | +$315K | ﹤0.01% | 4963 |
|
Bank of America's LUMO Position: Q4 2024 in Review
Bank of America sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 1,800 shares — an estimated $6.97K sold.
Bank of America first reported a position in LUMO in Q2 2013 and held it in 42 quarters. The position peaked at $1.74M in Q1 2018. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- Bank of America reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Bank of America sold 1,800 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $6.97K.
- Bank of America first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 42 quarters.
- Bank of America's Lumos Pharma, Inc. Common Stock position peaked at $1.74M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.